Rheumatoid Arthritis eJournal Club
   

Treating a Patient with RA and Hepatitis B or C

Print this Content
 
Release Date:  December 30, 2008 Renewal Date:  December 30, 2009 Expiration Date:  June 30, 2010

Technical Requirements
(will appear in new window)
 
Estimated Time of Completion 1 hour
Description / Overview The purpose of this activity is to review the management of and discuss the treatment options for a patient with rheumatoid arthritis (RA) who has hepatitis B or C.
Objectives At the conclusion of this activity, the participant will be able to:
  1. Identify the relevant factors for management of  a patient with RA who has hepatitis B or C.
  2. Review safety data concerning the use of conventional or biologic disease-modifying antirheumatic drugs (DMARDs) in a patient with RA who has hepatitis B or C.
  3. Discuss treatment options for a patient with RA who has hepatitis B or C.
Target Audience This activity is directed to rheumatologists and primary care physicians who treat patients with RA.
Accreditation The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio

Author / Faculty Dimitrios Vassilopoulos, MD
Assistant Professor of Medicine—Rheumatology
Athens University School of Medicine
Athens, Greece
Faculty Disclosure In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:

Leonard Calabrese, DO
  Consulting: Abbott Laboratories;
Elan Pharmaceuticals, Inc.;
Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.

The following faculty has indicated he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:

Dimitrios Vassilopoulos, MD

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

Bristol – Myers Squibb Company, Genentech/Biogen Idec

Wyeth Pharmaceuticals

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME.

CME Disclaimer